On 4th September 2017, Germany together with a number of countries, pledged EUR 56.5 million during a fundraising event for GARDP hosted in Berlin by the German Federal Ministry of Health and the German Federal Ministry of Education and Research. Contributions were made by the Netherlands, Switzerland, South Africa, the Wellcome Trust, Luxembourg, the United Kingdom and Germany. This is an important step for GARDP in order to support the implementation of GARDP’s business plan and its R&D programmes. Learn more about the pledging event
GARDP’s first seven-year business plan outlines the overall R&D strategy, prioritization process, and sustainable access approach, and serves as a roadmap for its concrete R&D programmes for the coming years and is available. See reports & publications
Activity update on GARDP R&D programmes:
While significant achievements have been made in reducing mortality in children under age five, mortality remains a burden in children less than one month of age with antimicrobial resistance posing a particular threat. This programme aims to develop and deliver a new first-line treatment for pathogens causing neonatal sepsis as well as a new treatment for confirmed multi-drug resistant pathogens. Two target product profiles have been generated to guide the development of the new treatments.
- The Programme has been launched – on target – to start pharmacokinetic and observational studies by end 2017/early 2018; stewardship and access plan under development and programme strategy to be published.
With the disengagement from antibiotic R&D of many of the large pharmaceutical actors, much of the knowledge and material resources that were part of the ‘golden era’ of antibiotic drug discovery and development have been forsaken. This programme aims to recover the knowledge, contacts, data, and assets of forgotten, abandoned, or withdrawn antibiotics as a ‘bridging’ measure while the search for new classes of antibiotics is being pursued and while, hopefully, a new generation of researchers in antibiotic R&D is stimulated and rebuilt.
- The Programme was presented on 6th September 2017 at ASM Microbe, Boston. Over 400 experts have been identified, 130 of whom have agreed to participate in the ‘REVIVE’ portal, which is slated to go live in November 2017, with five live webinars and workshops planned in 2017-2018. Five companies have been approached with 16 potential candidate molecules identified. Key collaborations have been built with CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), the Pew Charitable Trusts, and the Advanced Course on Antibiotics (AdCAb) co-organized by the Fondation Mérieux and Institut Pasteur.
Over the past few years, serious concerns have been raised globally over the spread of resistant gonorrhoea. Neisseria gonorrhoeae is threatening to soon become untreatable due to its resistance to all available classes of available antimicrobials. This programme will seek to develop and deliver two new treatments for gonorrhoea patients with drug-resistant infections by combining existing antibiotics and by exploring new antibiotics that are already in development. Two target product profiles have been developed to guide the project.
- The Programme was launched in July 2017, at the STI and HIV World Congress, in Rio de Janeiro. GARDP’s STI R&D strategy was jointly published with WHO in PLOS Medicine A partnership has been signed with Entasis Therapeutics to develop zoliflodacin, a novel first-in-class oral antibiotic, and one of the only treatments in development to address the rapidly-growing threat of drug-resistant gonorrhoea. Read press release
Paediatric Antibiotic Platform
This Programme aims to establish a platform to optimize current and new antibiotics for children through improvements in dose, duration, formulation or through combinations based on the gap analysis that will be undertaken with WHO. Depending on the outputs of the initial scoping exercise to be undertaken throughout 2017, approximately two projects are anticipated.
- Exploratory work is being undertaken with key stakeholders, including Médecins Sans Frontières/Doctors Without Borders, with an initial gap and opportunity analysis under way. A draft programme is under review.